|
NAA25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.09414732619007E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.48550002801551E-09 |
| Normal-vs-Stage2 |
8.60680000047687E-07 |
| Normal-vs-Stage3 |
1.53710377759353E-11 |
| Normal-vs-Stage4 |
4.01669808525185E-11 |
| Stage1-vs-Stage2 |
7.963400E-01 |
| Stage1-vs-Stage3 |
1.071410E-01 |
| Stage1-vs-Stage4 |
1.671920E-02 |
| Stage2-vs-Stage3 |
3.698200E-01 |
| Stage2-vs-Stage4 |
1.285390E-01 |
| Stage3-vs-Stage4 |
4.002400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.21890053605966E-10 |
| Normal-vs-AfricanAmerican |
2.979900E-04 |
| Normal-vs-Asian |
7.3671000411224E-09 |
| Caucasian-vs-AfricanAmerican |
4.729400E-01 |
| Caucasian-vs-Asian |
8.981200E-01 |
| AfricanAmerican-vs-Asian |
3.675200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.08389963671129E-11 |
| Normal-vs-Female |
8.6395002263373E-11 |
| Male-vs-Female |
5.683000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.41810008180698E-10 |
| Normal-vs-Age(41-60Yrs) |
3.94169996642546E-09 |
| Normal-vs-Age(61-80Yrs) |
4.47569981076867E-10 |
| Normal-vs-Age(81-100Yrs) |
2.648800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.786200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.275000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.669200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.666400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.456800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.410600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.168300E-02 |
| Classical-VS-Follicular |
7.680200E-01 |
| Classical-VS-Other |
3.778200E-01 |
| Classical-VS-Normal |
2.59540167135697E-11 |
| Tall-VS-Follicular |
7.818300E-02 |
| Tall-VS-Other |
7.437600E-01 |
| Tall-VS-Normal |
3.1767999342236E-10 |
| Follicular-VS-Other |
6.179800E-01 |
| Follicular-VS-Normal |
1.3389999999891E-06 |
| Other-VS-Normal |
2.038200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.75379710753987E-11 |
| Normal-vs-N1 |
2.83409995471828E-09 |
| N0-vs-N1 |
4.747200E-01 |
|
|
